Humacyte, Inc

Contributing Author

Recent Articles by Humacyte, Inc

Aug-24	Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions HUMA GlobeNewswire
Aug-19	Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results HUMA +26.34% GlobeNewswire
Aug-18	Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess Implantation; Cites Bioengineered Blood Vessel as "Revolutionary Advancement" HUMA GlobeNewswire
Aug-12	Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update HUMA -6.34% GlobeNewswire
Aug-07	Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026 HUMA GlobeNewswire
Jul-27	Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting HUMA +7.89% GlobeNewswire
Jul-14	Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access HUMA GlobeNewswire
Jun-15	Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting HUMA GlobeNewswire
Jun-10	Humacyte, Inc. Announces Pricing of Public Offering of Common Stock HUMA -19.40% GlobeNewswire
Jun-10	Humacyte, Inc. Announces Proposed Public Offering of Common Stock HUMA -19.40% GlobeNewswire
Jun-10	Humacyte, Inc. Announces Proposed Public Offering of Common Stock HUMA HUMA -19.40% GlobeNewswire
Jun-10	Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients HUMA HUMA -19.40% GlobeNewswire
May-26	Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access HUMA +5.71% GlobeNewswire
May-20	Humacyte Announces Symvess is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs HUMA +11.14% GlobeNewswire
May-13	Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update HUMA +24.18% GlobeNewswire
May-12	Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer HUMA -9.00% GlobeNewswire
May-08	Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026 HUMA GlobeNewswire
Apr-27	Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 HUMA +15.13% GlobeNewswire
Apr-24	Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess HUMA GlobeNewswire
Apr-22	Humacyte Appoints Jim Mercadante as Chief Commercial Officer HUMA +6.97% GlobeNewswire
Apr-21	Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Trauma Repair HUMA GlobeNewswire
Mar-27	Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update HUMA -13.21% GlobeNewswire
Mar-26	Humacyte Appoints Rick McElheny as Senior Vice President of Business Development HUMA -5.42% GlobeNewswire
Mar-23	Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 HUMA +8.61% GlobeNewswire
Mar-19	Humacyte Receives Symvess Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia HUMA -19.42% GlobeNewswire
Mar-19	Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock HUMA -19.42% GlobeNewswire
Mar-17	Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair HUMA GlobeNewswire
Mar-02	Humacyte To Participate in Upcoming Investor Conferences HUMA GlobeNewswire
Feb-18	Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting HUMA -5.26% GlobeNewswire
Feb-09	Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels HUMA +30.02% GlobeNewswire
Jan-08	Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications HUMA GlobeNewswire
Jan-05	Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel HUMA +8.72% GlobeNewswire
Dec-22	Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess in Extremity Trauma Repair HUMA GlobeNewswire
Dec-16	Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital HUMA -5.08% GlobeNewswire
Nov-20	Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV) Clinical Results HUMA GlobeNewswire
Nov-13	Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) HUMA GlobeNewswire
Nov-12	Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update HUMA GlobeNewswire
Nov-10	Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 HUMA GlobeNewswire
Nov-06	Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 HUMA -9.66% GlobeNewswire
Oct-30	Humacyte Announces Publication of New Data Comparing Symvess to Autologous Vein in Extremity Arterial Trauma HUMA GlobeNewswire
Oct-07	Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering HUMA -33.67% GlobeNewswire
Oct-06	Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess HUMA +18.10% GlobeNewswire
Sep-29	Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus HUMA GlobeNewswire
Sep-18	Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) HUMA +16.99% GlobeNewswire
Sep-15	Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess HUMA GlobeNewswire
Aug-11	Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update HUMA -29.64% GlobeNewswire
Aug-07	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 HUMA +11.76% GlobeNewswire
Jul-23	Humacyte Announces First Symvess Sale to Military Treatment Facility HUMA +18.70% GlobeNewswire
Jul-08	Humacyte announces Symvess ECAT Approval from U.S. Defense Logistics Agency HUMA +18.98% GlobeNewswire
Jun-09	Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting HUMA GlobeNewswire
Jun-02	Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 HUMA GlobeNewswire
May-19	Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq HUMA HUMA +11.66% GlobeNewswire
May-13	Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update HUMA +31.06% GlobeNewswire
May-09	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 HUMA GlobeNewswire

Humacyte, Inc

Recent Articles by Humacyte, Inc

Upgrade your Finviz experience